Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia.

Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia.
Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia. Expert Opin Pharmacother. 2019 May 06;:1-7 Authors: Müller T, Kuhn W, Möhr JD Abstract INTRODUCTION: Amantadine is an old, antiviral compound that moderately ameliorates impaired motor behaviour in Parkinson's disease. Its current resurgence results from the novel retarded release amantadine hydrochloride formulation, ADS5102, which has also received approval ... read more
Source: PubMedPublished on 2019-05-07